Compugen(US:CGEN)2026-03-02 14:30Financial Data and Key Metrics Changes - The company reported approximately $67.3 million in revenues for Q4 2025 and approximately $72.8 million for the full year 2025, compared to approximately $1.5 million and $27.9 million for the same periods in 2024, reflecting significant growth [17][18] - Net profit for Q4 2025 was approximately $56.8 million or approximately $0.60 per share, compared to a net loss of approximately $6.1 million or approximately $0.07 per share in Q4 2024 [19] - For the full year 2025, net profit was approximately $35.3 million or approximately $0.38 per share, compared to a net loss of approximately $14.2 million or approximately $0.16 per share in 2024 [20] Business Line Data and Key Metrics Changes - The company advanced its clinical programs, initiating new trials for COM-701 and GS-0321, with significant updates presented at major conferences [5][9] - The partnership with Gilead for GS-0321 includes potential future milestones of up to $758 million and tiered royalties [11] Market Data and Key Metrics Changes - The company extended its cash runway into 2029, assuming no further cash inflows, due to a non-dilutive transaction with AstraZeneca [4][6] - AstraZeneca's rilvegostomig is involved in a broad late-stage development program with an estimated peak annual revenue potential of over $5 billion [7] Company Strategy and Development Direction - The company aims to continue executing its MAIA-ovarian adaptive trial and expand its clinical development plan across ovarian cancer and other indications [9][10] - The leadership transition to a new CEO is expected to provide operational focus and strategic continuity for the company's growth [4][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products and the strategic execution of their clinical trials, particularly in the context of the competitive landscape [12][13] - The company remains committed to investing in its early-stage pipeline and leveraging its computational drug target discovery engine [13] Other Important Information - The company has a solid balance sheet with approximately $145.6 million in cash equivalents as of December 31, 2025 [16] - The company is focused on maintaining a favorable safety profile for its products while advancing innovative immune oncology therapies [12] Q&A Session Summary Question: Expectations for the 1Q 2027 update with COM-701 - Management indicated that data maturation is expected in 1Q 2027, with the timeline for registration dependent on the totality of the data [22][23] Question: Cadence of potential milestones for rilvegostomig - The next milestone payment of $25 million is expected upon BLA acceptance, with total remaining milestones up to $195 million [26][27] Question: Shift in interim analysis timing for the ovarian trial - The shift to Q1 2027 was due to slower opening of major academic sites, which are now all operational [30][31] Question: Discussions on expanding the use of COM-902 derived TIGIT - The company clarified that AstraZeneca controls rilvegostomig and is expanding its use, but discussions on COM-902 are separate [33] Question: Data reporting for GS-0321 - Data reporting will align with Gilead's guidelines, typically presented at scientific conferences, including activity and safety [34]